Incyte
INCY
Market cap $13.3B

68.59 USD

-1.75

2.49%

At close Jul 11, 4:00 PM EDT

After hours

68.59

+0.00

0.00%

1 day

-2.49%

5 days

0.51%

1 month

-0.38%

3 months

20.61%

6 months

-5.22%

Year to date

-1.35%

1 year

10.11%

5 years

-31.79%

10 years

-39.30%

About: Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Employees: 2,617

Healthcare Biotechnology

0

Funds holding %

of 7,312 funds

0

Analysts bullish %

of 6 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

57% more call options, than puts

Call options by funds: $47.5M | Put options by funds: $30.3M

16% more repeat investments, than reductions

Existing positions increased: 252 | Existing positions reduced: 217

2.38% more ownership

Funds ownership: 94.68% [Q4 2024] → 97.07% (+2.38%) [Q1 2025]

4% less funds holding

Funds holding: 637 [Q4 2024] → 614 (-23) [Q1 2025]

10% less capital invested

Capital invested by funds: $12.6B [Q4 2024] → $11.4B (-$1.23B) [Q1 2025]

11% less first-time investments, than exits

New positions opened: 73 | Existing positions closed: 82

50% less funds holding in top 10

Funds holding in top 10: 8 [Q4 2024] → 4 (-4) [Q1 2025]

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$59

14%

downside

Avg. target

$73

6%

upside

High target

$107

56%

upside

6 analyst ratings

1 positive

17%

5 neutral

83%

0 negative

0%

Stifel Stephen Willey	56%upside $107	Buy Upgraded	16 Jun 2025
UBS Ashwani Verma	11%downside $61	Neutral Maintained	3 Jun 2025
Truist Securities Srikripa Devarakonda	6%upside $73	Hold Maintained	27 May 2025
Wells Fargo Derek Archila	14%downside $59	Equal-Weight Maintained	30 Apr 2025
RBC Capital Brian Abrahams	2%downside $67	Sector Perform Maintained	30 Apr 2025

See Analyst Rankings

Financial journalist opinion

Based on 16 articles about INCY published over the past 30 days

Zacks Investment Research

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Incyte to Report Second Quarter Financial Results

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 29, 2025. The schedule for the press release and conference call/webcast is as follows: Q2 2025 Press Release: July 29, 2025 at 7:00 a.m. ET Q2 2025 Conference Call: July 29, 2025 at 8:00 a.m. ET Domestic Dial-In Number: 877-407-3042 International Dial-In Number: 201-389-0864 Conference ID Number: 1375458.

Incyte to Report Second Quarter Financial Results

Incyte: New CEO Brings A New Possible Outcome

Incyte's new CEO, Bill Meury, signals a potential strategic pivot toward M&A, leveraging his biopharma acquisition experience. Jakafi and Opzelura remain the company's primary revenue drivers, with Jakafi delivering $709M in Q1 2025 and strong growth across indications. Q1 2025 revenue grew 20% year-over-year to $1.05B, prompting management to raise full-year guidance, reflecting confidence in core products.

Incyte: New CEO Brings A New Possible Outcome

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Zacks Investment Research

Incyte Gains 9.2% in Three Months: Buy, Hold or Sell the Stock?

INCY stock climbs 9.2% in three months as FDA approvals and a new diagnostic deal fuel pipeline momentum.

Incyte Gains 9.2% in Three Months: Buy, Hold or Sell the Stock?

Investors Business Daily

Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes

Incyte stock popped Thursday after the company's board appointed Bill Meury as its new CEO, replacing Herve Hoppenot, who is retiring.

Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes

Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire.

Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire

Zacks Investment Research

FDA Extends INCY's Application for Opzelura Label Expansion

FDA extends review of Incyte's ruxolitinib cream for children with atopic dermatitis, delaying decision to September 2025.

FDA Extends INCY's Application for Opzelura Label Expansion

Incyte Says FDA Extended Review Period for Opzelura

Incyte said federal regulators have extended the review period for evaluating its Opzelura cream as a treatment for moderate atopic dermatitis in children aged 2 to 11.

Incyte Says FDA Extended Review Period for Opzelura

Zacks Investment Research

Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma

The FDA approves INCY's Monjuvi in combination with rituximab and lenalidomide for relapsed/refractory follicular lymphoma, its second approved indication.

Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma

See News Rankings

Charts implemented using Lightweight Charts™